NCFB Programme

About Santero Therapeutics

Santero Therapeutics is a private, preclinical-stage biotech tackling a major unmet need in chronic bacterial infections. The company's innovative platform targets the RelA/SpoT homolog (RSH) enzymes, a master switch for bacterial dormancy, with two distinct mechanisms: direct bactericidal activity and resensitization of dormant bacteria to standard-of-care antibiotics. Its lead program is focused on non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa infection, a population with high morbidity and mortality, and it has broad potential across multiple chronic and acute refractory infections.

Therapeutic Areas